Pay in 4 interest-free payments of $6.49 Learn more
Ships within 48 hours · Estimated delivery Oct 1 - Oct 6
There is evidence that controlling acidosis reduces mitochondrial dysfunction in shock
Talk to your healthcare provider if you are pregnant or plan to become pregnant
Retatrutide (LY3437943) is a next-generation triple-acting agonist that simultaneously targets GIP (glucose-dependent insulinotropic polypeptide), GLP-1 (glucagon-like peptide-1), and glucagon receptors
It no longer advertises compounded GLP-1s and now offers them only on a limited basis, when a provider determines a compounded product is clinically necessary for a patient who cannot use the commercial options
US$ 29.91
US$ 29.54
US$ 23.55
US$ 24.20
US$ 22.79
US$ 24.41
US$ 28.32
US$ 29.64
US$ 29.21
US$ 21.81
US$ 22.95
US$ 22.14
